Targeting MYC with antisense oligonucleotides
The realization of direct-acting agents targeting the MYC oncogene has been a long-standing challenge in cancer therapeutics. Our recent paper describes new antisense tools with potent anti-MYC effects.
Tumor evolution selectively inactivates the core microRNA machinery for immune evasion
Here we investigate the impact of different immune pressure on tumor clonal dynamics and immune evasion mechanism, by combining massive parallel sequencing of immune edited tumors and CRISPR library screens in syngeneic mouse tumor model and co-culture system.
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer
In this clinical study, we have validated a 44 gene expression based DDIR signature as a predictor of response to neoadjuvant chemotherapy in breast cancer, which can be integrated into clinical workflows, and potentially identifies a subgroup of cancers responsive to anthracycline treatment.
